Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06069713 · ClinicalTrials.gov registry record · NA
Consumer Perceptions of Cannabidiol (CBD) Health Claims
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 3,504
- Enrollment target
NCT06069713 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 3,504 participants.
The verdict
NCT06069713, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,504 participants
- Enrollment target
Study Summary
Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may reduce perceptions of harm and increase perceived benefits of use. This study aims to evaluate how consumers perceive real-world CBD advertisements. To that end, we will implement an online survey and randomize adult participants (ages 18-65) to see various advertisements made about CBD to determine if they interpret advertisements as making health claims that are currently prohibited by the FDA.
Interventions
- BEHAVIORAL CBD advertisements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,504 participants |
| Start Date | 2023-10-09 |
| Est. Completion | 2023-11-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06069713
The ClinicalTrials.gov registry entry for NCT06069713 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBD advertisements is the first listed.
NCT06069713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06069713 about?
NCT06069713 is a clinical study titled "Consumer Perceptions of Cannabidiol (CBD) Health Claims". Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as ha...
What is the current status of trial NCT06069713?
This trial is currently completed. It is a NA study. The enrollment target is 3,504 participants. The study started on 2023-10-09. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT06069713?
The interventions under investigation include: CBD advertisements (BEHAVIORAL).
Who is sponsoring clinical trial NCT06069713?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.